Our research focuses on understanding the fundamental and functional aspects of pharmacokinetics-pharmacodynamics (PKPD) in health and disease.
Within the area of translational PKPD we address conversion of pharmacokinetic data from the preclinical to the clinical setting. This is strongly needed for optimizing drug discovery processes and promoting efficient treatment of CNS diseases.
We are interested in brain drug delivery in relation to transport processes of both small and large molecules across the blood brain barrier (BBB), where a quantitative role of nanocarriers is specifically studied.
Using the concepts and methodologies developed for the brain we are also exploring drug distribution in the lung. This is important for the design and evaluation of lung targeted drugs which may be administered by inhalation.
For this purpose, methods are being developed to help analyzing the pharmacologically relevant unbound concentrations in brain and other tissues.
Our work also emphasizes the importance of bridging the expertise within academia and pharmaceutical industry in order to seek excellence in method development for better therapeutics treating CNS and lung disorders.
Principal investigator: Margareta Hammarlund-Udenaes
The Neurovascular Unit (NVU): The BBB is a functional and dynamic interface between blood and brain. It protects the brain but it is also the major hindrance for successful treatment of CNS disorders. Accumulating evidence indicates that the BBB and the whole NVU play an important role in disease etiology and progression and may as such affect drug delivery to the brain (picture by T Näsström).